Compare ArcelorMittal SA (MT) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs Natera Inc. Common Stock — how do they compare? ArcelorMittal SA trades at $62.31 (market cap $47.40B), while Natera Inc. Common Stock trades at $403.64 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and ArcelorMittal SA pays a 0.96% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ArcelorMittal SA for 36 Days and Natera Inc. Common Stock for 0 Days on average.
| MT | NTRA | |
|---|---|---|
Market Cap | $47.40B | $57.03B |
Volume | 869,267 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $425.64 |
52-Week Low | $36.91 | $179.42 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $56.97B | $56.18B |
Dividend Yield | 0.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $63.47, up 0.83% on the day, with a bearish technical signal and neutral oscillators. Recent earnings show a Q2 2026 miss but Q1 and Q4 2025 beats, with revenue at $61.35B in 2025 and net income margin improving to 2.88%. The company faces operational disruptions in Ukraine, with a $1B impairment charge, but maintains a strong balance sheet with $6.40B cash and low debt levels.
The outlook is mixed: analyst consensus is bullish with a $74.33 price target, but risks include geopolitical issues and volatile steel demand. Upside potential exists from strategic growth projects and shareholder returns, yet investors must weigh the impact of recent impairments and industry headwinds on future performance.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
